AKT1 and neoplasm: Garofalo et al. for example, first showed that the oncogenic miR-221/222 induce TRAIL resistance in aggressive non-small cell lung cancer through the activation of the AKT pathway, by targeting PTEN and TIMP3 tumor suppressors [94].